Pharmacology
Summary
Narcolepsy is a neurological disorder marked by the brain's impaired ability to regulate sleep-wake cycles, leading to excessive daytime sleepiness. There are two main classifications: Narcolepsy type 1 (NT1), also known as narcolepsy with cataplexy, is distinguished by cataplexy, or a sudden and transient episode of muscle weakness. Additionally a diagnosis of NT1 can also be established with low orexin (hypocretin-1) even if cataplexy isn't evident. In contrast, narcolepsy type 2 primarily doesn't manifest with cataplexy or reduced orexin levels.
A central part of narcolepsy management includes the drugs armodafinil and modafinil. These medications are believed to exert their therapeutic effects by modulating dopamine levels, thereby mitigating the excessive daytime sleepiness associated with narcolepsy. Due to their stimulating properties, which can induce feelings of euphoria and mood changes, there's a potential for abuse. As the R-enantiomer to modafinil's S-enantiomer, armodafinil has a longer half-life and may offer longer wake-promotion. Nonetheless, when prescribing these medications, clinicians need to be wary of several factors: their effects on CYP450 enzymes, potential risks during pregnancy, the emergence of severe rashes that may progress to Stevens-Johnson syndrome (SJS), neuropsychiatric symptoms, and the added caution required for those with pre-existing cardiovascular disease.
Lesson Outline
Don't stop here!
Get access to 133 more Pharmacology lessons & 13 more medical school learning courses with one subscription!
FAQs
Narcolepsy type 1 (NT1) is distinctively marked by the presence of cataplexy, which is a sudden and brief loss of muscle tone. While excessive daytime sleepiness is common in both types, a diagnosis of NT1 can also be established with low orexin (hypocretin-1) levels even if cataplexy isn't evident. In contrast, Narcolepsy type 2 (NT2) is characterized by excessive daytime sleepiness but without the accompanying cataplexy or lowered hypocretin-1 levels.
Armodafinil and modafinil are agents that are believed to exert their therapeutic effects by modulating dopamine levels, thereby mitigating the excessive daytime sleepiness associated with narcolepsy. A distinguishing feature between them is that armodafinil, as the R-enantiomer of modafinil, has a longer half-life than modafinil's S-enantiomer. This attributes armodafinil with enhanced efficacy in promoting sustained wakefulness.
Both armodafinil and modafinil have interactions with various drugs owing to their effects on liver enzymes. Specifically, they induce CYP3A4/5, potentially reducing the efficacy of hormonal contraceptives and cyclosporine. They also inhibit CYP2C19, which can increase levels of drugs like phenytoin and certain benzodiazepines. Additionally, these agents are linked to risks during pregnancy, including intrauterine growth restriction and spontaneous abortions. They can also instigate severe skin reactions like Stevens-Johnson Syndrome (SJS) and the drug reaction with eosinophilia and systemic symptoms (DRESS). Their use might be accompanied by psychiatric side effects such as anxiety, agitation, and mood disturbances.
For individuals with a background of psychiatric conditions like psychosis, depression, or mania, armodafinil and modafinil should be used judiciously due to their potential psychoactive effects. It's imperative to exercise caution or reconsider the use of these agents for those with pre-existing cardiovascular ailments, particularly in patients previously exposed to CNS stimulants and those with histories of left ventricular hypertrophy or mitral valve prolapse.
Armodafinil stands apart as the R-enantiomer of modafinil, implying that its composition is a singular, unblended form as opposed to the mixed R- and S-enantiomers found in modafinil. This gives armodafinil an extended half-life, enhancing its effectiveness in ensuring wakefulness throughout the day. Nonetheless, the pharmacological profiles, psychoactive properties, potential side effects, and drug interactions largely parallel between the two medications.
MCAT® is a registered trademark of the Association of American Medical Colleges. The United States Medical Licensing Examination (USMLE®) is a joint program of the Federation of State Medical Boards (FSMB®) and National Board of Medical Examiners (NBME®). NAPLEX® is a registered trademark of the National Association of Boards of Pharmacy. PANCE© is a registered trademark of the National Commission on Certification of Physician Assistants. NCLEX® is a registered trademark and service mark of the National Council of State Boards of Nursing, Inc. None of the trademark holders are endorsed by nor affiliated with Sketchy or this website.
